<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03066687</url>
  </required_header>
  <id_info>
    <org_study_id>CR108289</org_study_id>
    <secondary_id>42756493EDI1006</secondary_id>
    <nct_id>NCT03066687</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Effect of Food on the Pharmacokinetics of Erdafitinib in Healthy Participants</brief_title>
  <official_title>Randomized, Open-Label, 2-Way Crossover Study to Determine the Effect of Food on the Pharmacokinetics of Erdafitinib in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the effect of food on the relative
      bioavailability of a single 9 milligram (mg) oral dose of erdafitinib in healthy
      participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 14, 2017</start_date>
  <completion_date type="Actual">May 12, 2017</completion_date>
  <primary_completion_date type="Actual">May 12, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240, 288, and 366 hours post dose</time_frame>
    <description>The Cmax is the maximum observed plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC [0-last])</measure>
    <time_frame>Predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240, 288, and 366 hours post dose</time_frame>
    <description>The AUC (0-last) is the area under the plasma concentration-time curve from time zero to last quantifiable time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])</measure>
    <time_frame>Predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144, 192, 240, 288, and 366 hours post dose</time_frame>
    <description>The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC (last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Baseline, up to end of study (Day 15 of Period 2) or early withdrawal</time_frame>
    <description>Safety and Tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence 1: Erdafitinib 9 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 9 milligram (mg) dose of erdafitinib under fasted condition [Treatment A] in Period 1, and under fed (with high-fat and high-calorie breakfast) condition [Treatment B] in Period 2. Each Treatment Period will be separated by a washout of at least 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 2: Erdafitinib 9 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 9 mg dose of erdafitinib under fed (high-fat and high-calorie breakfast) condition [Treatment B] in Period 1, and under fasted condition [Treatment A] in Period 2. Each Treatment Period will be separated by a washout of at least 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erdafitinib</intervention_name>
    <description>Erdafitinib 9 mg (provided as one 4-mg tablet [G-024] and one 5-mg tablet [G-025]) will be administered orally on Day 1 in each Treatment Period of assigned sequence.</description>
    <arm_group_label>Treatment Sequence 1: Erdafitinib 9 mg</arm_group_label>
    <arm_group_label>Treatment Sequence 2: Erdafitinib 9 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to adhere to the prohibitions and restrictions specified in this
             protocol

          -  If a woman, must be not of childbearing potential: postmenopausal (greater than [&gt;] 45
             years of age with amenorrhea for at least 2 years, or any age with amenorrhea for at
             least 12 months and a serum follicle stimulating hormone [FSH] &gt;40 International Units
             Per Liter [IU/L]); or surgically sterile

          -  If a woman, must have a negative serum beta-human chorionic gonadotropin (hCG)
             pregnancy test at screening and on Day -1 of Period 1 and Period 2

          -  If a woman, must agree not to donate eggs (ova, oocytes) for the purposes of assisted
             reproduction during the study and for 3 months after the last study drug
             administration

          -  Body mass index (BMI; weight [kg]/height^2 [m]^2) between 18 and 32 kilogram per
             square meter (kg/m^2) (inclusive), and body weight not less than 50 kg

          -  Non-smoker for at least 6 months before first study drug administration

        Exclusion Criteria:

          -  History of or current clinically significant medical illness including (but not
             limited to) cardiac arrhythmias or other cardiac disease, hematologic disease,
             coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid
             abnormalities, significant pulmonary disease, including bronchospastic respiratory
             disease, diabetes mellitus, hepatic or renal insufficiency, thyroid disease,
             neurologic or psychiatric disease, infection, or any other illness that the
             investigator considers should exclude the participant or that could interfere with the
             interpretation of the study results

          -  History or current evidence of ophthalmic disorder, such as central serous retinopathy
             (CSR) or retinal vein occlusion, active wet age related macular degeneration, diabetic
             retinopathy with macular edema, uncontrolled glaucoma, corneal pathology such as
             keratitis, keratoconjunctivitis, keratopathy, corneal abrasion, inflammation or
             ulceration

          -  Clinically significant abnormal values for hematology, serum chemistry, or urinalysis
             at screening as deemed appropriate by the investigator

          -  Clinically significant abnormal physical examination, vital signs, or 12-lead
             electrocardiogram (ECG) at screening as deemed appropriate by the investigator

          -  Use of any prescription or nonprescription medication (including vitamins and herbal
             supplements), except for acetaminophen and hormonal replacement therapy, within 14
             days before the first dose of the study drug is scheduled until completion of the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2017</study_first_submitted>
  <study_first_submitted_qc>February 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2017</study_first_posted>
  <last_update_submitted>June 22, 2017</last_update_submitted>
  <last_update_submitted_qc>June 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

